TOP TIERMARKET NEWSWIRE
Movers explained · September 23, 2026

Why Is RELAY THERAPEUTICS I (RLAY) Stock Down Today?

By the Top Tier Newswire AI Desk · reviewed against 2 wire stories

RELAY THERAPEUTICS I (RLAY) is down -9.66% in the latest session. Our newswire has captured 2 stories on RLAY across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

The written analysis for RLAY publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.

RLAY by the numbers

Last: $17.48Session: -9.66%Coverage: 2 stories / 2 sourcesAI sentiment: 63/100 (bullish)
AI sentiment, last 36h · averaged over 2 stories · 63/100 bullish
AI sentiment 63/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 2 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowBusiness Insider · sentiment 63 · X-Chem Announces Phase 3 Milestone in Collaboration with Relay TherapeuticsBusiness Insider · 63X-Chem Announces Phase 3 Milestone in Collaboration with Relay TherapeuticsGlobeNewswire · sentiment 63 · X-Chem Announces Phase 3 Milestone in Collaboration with Relay TherapeuticsGlobeNewswire · 63X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
1d agoBusiness InsiderBULLISH 63Product/PR

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate...

1d agoGlobeNewswireBULLISH 63Product/PR

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate...

Frequently asked questions

Why is RLAY stock down today?

RELAY THERAPEUTICS I (RLAY) is down -9.66% in the latest session. Our newswire has captured 2 stories on RLAY across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100). The most recent driver: "X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics" (Business Insider).

Is RLAY a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of RLAY coverage reads 63/100 over 2 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on RLAY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.